Literature DB >> 12453321

N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.

Richard M Goldberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12453321     DOI： 10.1016/S1533-0028(11)70509-6

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  9 in total

1.  North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.

Authors:  Robert R McWilliams; Nathan R Foster; Michelle R Mahoney; Thomas C Smyrk; Joseph A Murray; Matthew M Ames; L Elise Horvath; Daniel J Schneider; Timothy J Hobday; Aminah Jatoi; Jeffrey P Meyers; Matthew P Goetz
Journal:  Cancer       Date:  2017-05-10       Impact factor: 6.860

2.  Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

Authors:  H S Hochster; A Grothey; L Hart; K Rowland; R Ansari; S Alberts; N Chowhan; R K Ramanathan; M Keaton; J D Hainsworth; B H Childs
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

3.  Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.

Authors:  Susanna V Ulahannan; Osama E Rahma; Austin G Duffy; Oxana V Makarova-Rusher; Metin Kurtoglu; David J Liewehr; Seth M Steinberg; Tim F Greten
Journal:  Hepat Oncol       Date:  2015-01-01

4.  Signet-ring cell carcinoma of the colon: A case report of a 9-year-old boy.

Authors:  Shaobo Yang; Gongbao Liu; Shan Zheng; Kuiran Dong; Yangyang Ma; Xianmin Xiao
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

5.  Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer.

Authors:  Qiuyan Song; Yuanxuan Cai; Kangyuan Guo; Min Li; Zaoqin Yu; Qirui Tai; Yuhang Zhao; Xuan Zhu; Chengliang Zhang
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

Review 6.  Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.

Authors:  O E Rahma; A Duffy; D J Liewehr; S M Steinberg; T F Greten
Journal:  Ann Oncol       Date:  2013-05-12       Impact factor: 32.976

7.  Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.

Authors:  John L Marshall; Daniel G Haller; Aimery de Gramont; Howard S Hochster; Heinz-Josef Lenz; Jaffer A Ajani; Richard M Goldberg
Journal:  Gastrointest Cancer Res       Date:  2007-07

8.  Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.

Authors:  Lindsay A Renfro; Fotios Loupakis; Richard A Adams; Matthew T Seymour; Volker Heinemann; Hans-Joachim Schmoll; Jean-Yves Douillard; Herbert Hurwitz; Charles S Fuchs; Eduardo Diaz-Rubio; Rainer Porschen; Christophe Tournigand; Benoist Chibaudel; Alfredo Falcone; Niall C Tebbutt; Cornelis J A Punt; J Randolph Hecht; Carsten Bokemeyer; Eric Van Cutsem; Richard M Goldberg; Leonard B Saltz; Aimery de Gramont; Daniel J Sargent; Heinz-Josef Lenz
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544

9.  Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion.

Authors:  Fedor Moiseenko; Nikita Volkov; Alexey Bogdanov; Michael Dubina; Vladimir Moiseyenko
Journal:  F1000Res       Date:  2017-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.